Edgewise Therapeutics (EWTX) Return on Capital Employed (2021 - 2026)

Edgewise Therapeutics has disclosed Return on Capital Employed across 6 years of filings, most recently posting 38.9% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 38.9%, down 107.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 38.9% (down 107.0% YoY), and the FY2025 annual result was 38.88%, up 189.0% from the prior year.
• Return on Capital Employed came in at 38.9% for Q1 2026 at Edgewise Therapeutics, down from 35.4% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 19.03% in Q1 2022 to a low of 38.9% in Q1 2026.
• The 5-year median for Return on Capital Employed is 29.28% (2024), against an average of 29.39%.
• Across the five-year window, Return on Capital Employed tumbled 1686 bps in 2023 and jumped 438 bps in 2024, its largest moves.
• Edgewise Therapeutics' Return on Capital Employed stood at 20.15% in 2022, then sank by 84 bps to 37.02% in 2023, then advanced by 10 bps to 33.42% in 2024, then fell by 6 bps to 35.4% in 2025, then slipped by 10 bps to 38.9% in 2026.
• The last three Return on Capital Employed figures came in at 38.9% (Q1 2026), 35.4% (Q4 2025), and 31.38% (Q3 2025), per Business Quant data.